LONDON, United Kingdom: GSK plc announced that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) for its respiratory syncytial virus (RSV) older adult vaccine candidate. MAAs may be eligible for accelerated assessment if the European Medicines Agency’s Committee for Medicinal Products for Human Use decides the product is of major interest for…